Relebactam
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Using no additional skill — this is a direct report-generation task per the fully-specified prompt template, not a coding/debugging/brainstorming task.
Relebactam: From Antibacterial Adjunct Therapy to Hyperamylasemia
One-Sentence Summary
Relebactam is a diazabicyclooctane β-lactamase inhibitor used exclusively as a fixed combination with imipenem/cilastatin (Recarbrio) to restore antibacterial activity against certain resistant gram-negative organisms. The TxGNN model’s top prediction points to Hyperamylasemia, but this candidate is currently supported by 0 clinical trials and 0 publications, and the model’s own rationale flags it as likely low-confidence noise due to the absence of any plausible biological mechanism.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Antibacterial adjunct (combination with imipenem/cilastatin, as in Recarbrio); no formal approved-indication text on file |
| Predicted New Indication | Hyperamylasemia |
| TxGNN Prediction Score | 99.22% |
| Evidence Level | L5 |
| EU Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, relebactam is a component of the imipenem/cilastatin/relebactam combination (Recarbrio), where it inhibits class A and C β-lactamases to protect imipenem from enzymatic degradation and restore susceptibility of certain resistant gram-negative pathogens. It has no independent antibacterial activity and is never used as a standalone agent.
There is no established or plausible mechanistic pathway connecting a β-lactamase inhibitor to amylase metabolism or pancreatic/salivary gland function. The evidence pack’s own mechanistic rationale explicitly characterizes this top-ranked prediction as biologically implausible (“TxGNN 分數雖高但缺乏生物學合理性，判定為模型雜訊/低可信度預測”) — i.e., a high model score without a credible biological basis, most likely statistical noise from the knowledge graph rather than a genuine repurposing signal.
Reviewing the full set of 10 predictions in this pack, all are scored L5 (model prediction only, no supporting trials or literature) and all carry a “Hold” recommendation. Notably, rank 10 (septicemic plague) is the only candidate with an internally noted mechanistic rationale of any substance — theoretical antibacterial activity of imipenem/relebactam against Yersinia pestis — though it too lacks any direct clinical or literature support. This further underscores that the current candidate set does not meet the bar for advancement.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
EU Market Information
This drug currently holds no EU marketing authorizations (market status: not marketed; 0 licenses on file).
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: No clinical trials or literature support the top-ranked predicted indication, and the mechanistic rationale itself identifies the prediction as likely model noise rather than a genuine signal. Evidence across all 10 ranked candidates in this pack is uniformly L5 with no corroborating data.
To proceed, the following is needed:
- TFDA/SmPC warnings and contraindications (currently a blocking data gap — required before any S1 safety review)
- Mechanism of action (MOA) detail from DrugBank or the manufacturer (currently a data gap; needed to properly assess mechanistic plausibility)
- Confirmed original approved indication text (imipenem/cilastatin/relebactam combination use is inferred, not sourced from official labeling)
- If reconsidering any candidate from this set, prioritize septicemic plague (rank 10) for a targeted literature/preclinical search given its comparatively stronger — though still unverified — mechanistic rationale
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.